MARKET

APLS

APLS

Apellis Pharmace
NASDAQ
16.97
-0.67
-3.80%
After Hours: 16.99 +0.02 +0.12% 19:54 03/27 EDT
OPEN
17.55
PREV CLOSE
17.64
HIGH
17.61
LOW
16.97
VOLUME
1.76M
TURNOVER
--
52 WEEK HIGH
30.48
52 WEEK LOW
16.10
MARKET CAP
2.17B
P/E (TTM)
95.61
1D
5D
1M
3M
1Y
5Y
1D
Is It Time To Reconsider Apellis Pharmaceuticals (APLS) After Its Recent Share Price Slump?
Simply Wall St · 1d ago
Mizuho Securities Remains a Hold on Apellis Pharmaceuticals (APLS)
TipRanks · 2d ago
Weekly Report: what happened at APLS last week (0316-0320)?
Weekly Report · 5d ago
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story
The Motley Fool · 6d ago
Apellis Pharmaceuticals Price Target Cut to $31.00/Share From $35.00 by Cantor Fitzgerald
Dow Jones · 03/18 13:50
Apellis Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald
Dow Jones · 03/18 13:50
Cantor Fitzgerald Maintains Overweight on Apellis Pharmaceuticals, Lowers Price Target to $31
Benzinga · 03/18 13:40
Cantor Fitzgerald Reaffirms Their Buy Rating on Apellis Pharmaceuticals (APLS)
TipRanks · 03/18 11:35
More
About APLS
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan) is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and the United Kingdom.

Webull offers Apellis Pharmaceuticals Inc stock information, including NASDAQ: APLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APLS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APLS stock methods without spending real money on the virtual paper trading platform.